ShlomoYanai in his new role, will work with the company’s other directors and its leadership team to formulate and execute Cambrex’s growth strategies.
Cambrex board of directors chairman John Miller said, "His in-depth knowledge of our industry will enhance our ability to build on the progress we’ve made and will provide us with valuable insight as we seek and evaluate growth opportunities."
Cambrex president and chief executive officer Steven Klosk said, "Shlomo’s outstanding background in the pharmaceutical industry will be a great asset to us as we continue to implement our strategic initiatives to grow sales of active pharmaceutical ingredients and finished dosage form products for the branded and generic markets."
Cambrex non-executive vice chairman Shlomo Yanai said, "The Cambrex team has been very successful in propelling the worldwide growth of the Company and I am looking forward to contributing to the Company’s initiatives to continue this success."
Yanai, who worked as the president and chief executive officer of Teva Pharmaceutical till mid-2012, said he will work for the company’s success.